{
    "title": "115_hr5687",
    "content": "The Act is titled the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue orders requiring the implementation of technologies to mitigate drug abuse risks, after consulting stakeholders. The technologies must match the specific risk level of the drug listed in the application. The Secretary may issue orders to implement technologies to reduce drug abuse risks, ensuring they are appropriate for the specific risk level of the drug listed in the application. The orders may include various options for implementing these technologies and may reference packaging or disposal standards from recognized organizations. The Secretary may issue orders to implement technologies to reduce drug abuse risks for specific drug classes, with compliance requirements for holders of covered applications to submit proposed changes within a specified timeframe. The Secretary may specify a longer time period for compliance with orders to implement changes for drug abuse risks. Holders of applications can request an alternative date within 60 days, which must be agreed upon by the Secretary. Changes approved in supplements must be implemented within 90 days of approval or a longer period approved by the Secretary. The holder of a covered application can request a longer compliance period for implementing changes to mitigate drug abuse risks. Alternative technologies, controls, or measures can be proposed and approved if they can effectively reduce the risk of abuse. Disputes regarding submitted supplements can be appealed by the holder of the application. The holder of a covered application can appeal a determination made regarding a supplement using dispute resolution procedures. Definitions include 'covered application' for drugs containing opioids in schedule II or III and 'relevant stakeholders' such as industry experts, manufacturers, healthcare providers, and others. The curr_chunk discusses prohibited acts related to drug approval under a covered application and required content of an Abbreviated New Drug Application. It involves various stakeholders such as care providers, pharmacists, manufacturers, and government agencies. The curr_chunk amends clauses related to drug approval and Abbreviated New Drug Application under the Federal Food, Drug, and Cosmetic Act. It includes provisions for opioids and technologies for packaging and disposal of drugs. The curr_chunk amends drug approval clauses under the Federal Food, Drug, and Cosmetic Act by adding provisions for opioids and technologies related to packaging and disposal of drugs. It includes requirements for drug applicants to propose measures that provide comparable protections to those required for the applicable listed drug. The curr_chunk clarifies that certain changes to drug labeling and conditions of use will not affect the approval of new drug applications. It also specifies that data requested by the Secretary of Health and Human Services for drug approval will not be limited by certain provisions. The Secretary of Health and Human Services may request data for making determinations under section 505-2. The GAO will report on the effectiveness of in-home controlled substance disposal products and packaging technologies, barriers to their use, and federal oversight. Federal oversight of site-of-use, in-home controlled substance disposal products includes identification of overseeing agencies, recommended disposal methods, and effectiveness in preventing diversion of prescribed substances. Federal oversight of controlled substance packaging technologies involves identifying overseeing agencies, recommended technologies like unit dose packaging, and other systems to mitigate abuse or misuse. The recommendations include evaluating site-of-use controlled substance disposal products for Federal oversight and determining the role of the Federal Government in ensuring product efficacy. The House of Representatives passed the bill on June 19, 2018. Karen L. Haas is the Clerk."
}